Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of TopotectTM (Dexrazoxane) for Accidental Extravasation of Anthracyclines

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Cancer patients treated with anthracycline~2. Informed consent obtained from the patient.~3. Suspicion of anthracycline extravasation is defined as:~   A primary assessment by the physician on duty, which would activate the standard departmental procedure for treatment of anthracycline extravasation.~   The presence of at least one of the following:~  * pain~  * swelling~  * redness~4. The Topotect infusion must be started \<6 hours after the accident.~5. The patient must be at least 18 years of age.~6. Performance status (PS) ≤2.~7. Suspicion of anthracycline extravasation from a central venous access device. -~Exclusion Criteria:~1. Known allergy towards dexrazoxane.~2. Reasonable suspicion of extravasation by other compounds than anthracyclines through the same intravenous access, e.g. vincristine, mitomycin, and vinorelbine, all of which may cause ulceration.~3. AST, ALT, bilirubin, LDH, serum alkaline phosphatase \>3 x upper normal value~4. Neutropenia and thrombocytopenia ≥ CTC grade 2~5. Pregnant or nursing women~6. Women of childbearing age and potential, where the patient does not agree to use an efficient contraceptive (e.g. birth control pill or an intra-uterine device for 3 months previous to start of the trial medication or diaphragm plus a spermicide).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).